Halaven (eribulin mesylate) / Eisai 
Welcome,         Profile    Billing    Logout  
 71 Diseases   105 Trials   105 Trials   2830 News 


«12...2021222324252627282930...3738»
  • ||||||||||  bintrafusp alfa (M7824) / EMD Serono, Halaven (eribulin mesylate) / Eisai
    Trial completion date, Trial primary completion date, Metastases:  M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer (clinicaltrials.gov) -  Dec 29, 2019   
    P1,  N=20, Recruiting, 
    Trial primary completion date: Aug 2019 --> Aug 2020 Trial completion date: Oct 2020 --> Oct 2021 | Trial primary completion date: Oct 2019 --> Oct 2021
  • ||||||||||  Halaven (eribulin mesylate) / Eisai
    Trial completion date, Trial primary completion date, Metastases:  E-SPEC: Eribulin Treatment as 1st-line or 2nd-line Chemotherapy for HER2-negative Hormone-resistant Inoperable or Recurrent Metastatic Breast Cancer (clinicaltrials.gov) -  Dec 24, 2019   
    P=N/A,  N=120, Active, not recruiting, 
    Therefore, further evaluation is warranted to determine whether eribulin ± trastuzumab therapy may be a potential option for first-line treatment in some patients with metastatic breast cancer who were recently treated in the neoadjuvant setting. Trial completion date: Jul 2020 --> Mar 2020 | Trial primary completion date: Jul 2020 --> Mar 2020
  • ||||||||||  Halaven (eribulin mesylate) / Eisai
    Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy:  Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies (clinicaltrials.gov) -  Dec 20, 2019   
    P1/2,  N=44, Active, not recruiting, 
    The combination of capecitabine and eribulin showed promising efficacy with manageable tolerability in patients with MBC. Recruiting --> Active, not recruiting | Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Dec 2019
  • ||||||||||  Halaven (eribulin mesylate) / Eisai
    Review, Journal, PARP Biomarker, IO Biomarker:  Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future Scenarios. (Pubmed Central) -  Nov 27, 2019   
    In this review, we aim to analyze a wide range of cumulated evidence on eribulin use in TNBC including preclinical studies, intervention and observational clinical trials. Data from the real-world setting and the emerging evidence increasingly substantiating the rationale for combinations with new generation treatment strategies, e.g., PARP-inhibitors, immune checkpoint inhibitors, will be also discussed.
  • ||||||||||  Halaven (eribulin mesylate) / Eisai
    IMMUNOLOGICAL EFFECTS OF ERIBULIN MESYLATE ADMINISTRATION IN PATIENTS WITH ADVANCED BREAST CANCER () -  Nov 23, 2019 - Abstract #AIOM2019AIOM_78;    
    In particular, during treatment, regulatory activities in T cells were increased through a decrease of Foxp3+Treg cells. These findings suggest a contribution of the immune cells to the antitumor activities of EM and may help to design relevant clinical protocols based on the combination of EM with immune checkpoint blockers.
  • ||||||||||  Halaven (eribulin mesylate) / Eisai
    TREATMENT WITH ERIBULIN MESILATE(EM) IN NINETIES WOMEN (NW)WITH LOCALLY ADVANCED BREAST CANCER NOT RESPONDING TO ENDOCRINOTHERAPY(NRETH):TOXICITY EVALUATION () -  Nov 23, 2019 - Abstract #AIOM2019AIOM_71;    
    These findings suggest a contribution of the immune cells to the antitumor activities of EM and may help to design relevant clinical protocols based on the combination of EM with immune checkpoint blockers. EM adj schedule in the treatment of LABC NRETh about ninety women shows good safety also in presence of comorbidity and frailty with 65-70% of Clinical Benefit.These data also show that subjects at a very advanced age better withstand this type of chemotherapy even compared to endocrine therapy [ic1] Authors suggest starting an enlarged polycentric study to confirm these outcomes.
  • ||||||||||  Halaven (eribulin mesylate) / Eisai
    ERIBULIN MESYLATE-TREATED METASTATIC BREAST CANCERS DEVELOP PROGRESSION MAINLY ON PRE-EXISTING LESIONS () -  Nov 23, 2019 - Abstract #AIOM2019AIOM_66;    
    This observation could be interpreted as being linked to an inhibition of the metastatic capacity of the tumor induced by the drug and is consistent with preclinical findings; furthermore, the better survival of PEL-progressive-pts could be interpreted as related to the acquisition of a more indolent phenotype caused by the exposure to EM. Further studies aimed to investigate the correlations between EM-induced bio-molecular modifications and clinical observations are needed.
  • ||||||||||  Halaven (eribulin mesylate) / Eisai
    Clinical, Journal:  Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancer. (Pubmed Central) -  Nov 21, 2019   
    We review recent pharmacological and clinical findings pertaining to eribulin use in metastatic breast cancer - particularly highlighting eribulin in difficult-to-treat and aggressive disease, and safety data in specific patient populations. Additionally, recent advancements in our understanding of the mechanism of action of eribulin and potential future directions for its clinical development are discussed. Ongoing studies of eribulin in combination with immunotherapies and established cytotoxic agents may help shape the future landscape of breast cancer treatment.
  • ||||||||||  paclitaxel trevatide (ANG1005) / Angiochem
    Trial completion date, Trial primary completion date:  ANGLeD: ANG1005 in Leptomeningeal Disease From Breast Cancer (clinicaltrials.gov) -  Nov 20, 2019   
    P3,  N=150, Not yet recruiting, 
    Ongoing studies of eribulin in combination with immunotherapies and established cytotoxic agents may help shape the future landscape of breast cancer treatment. Trial completion date: Mar 2022 --> Jul 2022 | Trial primary completion date: Jun 2021 --> Oct 2021
  • ||||||||||  Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Metastases:  Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma (clinicaltrials.gov) -  Nov 2, 2019   
    P2,  N=8, Completed, 
    Eribulin was well tolerated, but there were no patients who demonstrated objective response, and all patients had progression prior to four months. Recruiting --> Completed | N=20 --> 8 | Trial completion date: Jul 2021 --> Oct 2019 | Trial primary completion date: Jul 2020 --> Oct 2019
  • ||||||||||  Clinical, Review, Journal:  Marine-Derived Anticancer Agents: Clinical Benefits, Innovative Mechanisms, and New Targets. (Pubmed Central) -  Nov 2, 2019   
    Approximately 50 years since the approval of cytarabine, the marine-derived anticancer pharmaceutical pipeline includes four approved drugs and eighteen agents in clinical trials, six of which are in late development. Thus, the dynamic pharmaceutical pipeline consisting of approved and developmental marine-derived anticancer agents offers new hopes and new tools in the treatment of patients afflicted with previously intractable types of cancer.
  • ||||||||||  Herceptin (trastuzumab) / Roche, Kisqali (ribociclib) / Novartis, Perjeta (pertuzumab) / Roche
    Trial completion date, Combination therapy, Metastases:  Detect V / CHEVENDO (Chemo vs. Endo) (clinicaltrials.gov) -  Oct 27, 2019   
    P3,  N=270, Recruiting, 
    Trial completion date: Jun 2019 --> Sep 2021 Trial completion date: Sep 2021 --> Jun 2023
  • ||||||||||  Yondelis (trabectedin) / J&J, Otsuka, PharmaMar, Halaven (eribulin mesylate) / Eisai
    Journal:  Pharmacotherapy for liposarcoma: current state of the art and emerging systemic treatments. (Pubmed Central) -  Oct 27, 2019   
    However, multiple clinical trials dedicated to patients with liposarcoma evaluating novel targeted agents are ongoing. Every effort should be made to enroll patients with liposarcoma into histotype-specific clinical trials.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Herceptin (trastuzumab) / Roche
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  PATRICIA: Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer (clinicaltrials.gov) -  Oct 21, 2019   
    P2,  N=232, Recruiting, 
    N=520 --> 300 | Trial primary completion date: Dec 2019 --> Dec 2020 Trial completion date: Dec 2019 --> Dec 2021 | Trial primary completion date: Sep 2019 --> Sep 2021
  • ||||||||||  vinorelbine tartrate / generics
    Review, Journal:  Systemic treatments of metastatic or locally recurrent adenoid cystic carcinoma of the head and neck, a systematic review (Pubmed Central) -  Oct 8, 2019   
    Many targetable molecular abnormalities have been identified and studies have shown prolonged stabilization with EGFR, VEGF and HDAC inhibitors. Multi-disciplinary collaborative consultation (MCC) meetings such as French network of experts in rare head and neck tumors (REFCOR) or Molecular MCC should be proposed and may allow referral to centers proposing specific therapeutic trials.
  • ||||||||||  Enrollment closed, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker, Metastases:  SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer (clinicaltrials.gov) -  Oct 8, 2019   
    P2,  N=1460, Active, not recruiting, 
    Multi-disciplinary collaborative consultation (MCC) meetings such as French network of experts in rare head and neck tumors (REFCOR) or Molecular MCC should be proposed and may allow referral to centers proposing specific therapeutic trials. Recruiting --> Active, not recruiting
  • ||||||||||  paclitaxel / Generic Mfg.
    In Vitro Assessment of the Impact of Chemotherapy Agents on Immune Cell Function (Prince George's Exhibition Halls AB) -  Oct 2, 2019 - Abstract #SITC2019SITC_937;    
    These data suggest that several of these agents could also negatively impact T-cell-driven anti-tumor responses. This understanding may help guide treatment selection and scheduling of optimal combination therapeutics with checkpoint inhibitors to broaden anti-tumor responses.
  • ||||||||||  doxorubicin hydrochloride / generics
    Which therapies for which molecular subgroups? (Hall A5) -  Sep 30, 2019 - Abstract #DGHO2019DGHO_1303;    
    Taken together, these novel therapies underline the importance of histology-driven therapy and of a greater understanding of the genomic complexities of STS. Given their variable genomic structure, histology-directed approaches should be regarded as the future of treatment for STS patients.
  • ||||||||||  doxorubicin hydrochloride / generics
    Practical news 2018/2019: ANNOUNCE & Co (Helsinki 1) -  Sep 30, 2019 - Abstract #DGHO2019DGHO_943;    
    However, results of the phase III trial (ANNOUNCE) demonstrated that the study did not meet its primary endpoint in the full study population or in the leiomyosarcoma sub-population; there was no difference in overall survival between the study arms for either population. Other interesting candidates being tested in phase III study concepts such as selinexor or carotuximab as well as ongoing national and international trials of interest will be presented in this update.
  • ||||||||||  Halaven (eribulin mesylate) / Eisai
    Enrollment open, Trial completion date, Trial primary completion date:  ERIBRAIN: Eribulin in Brain Metastases From HER2-negative Breast Cancer (clinicaltrials.gov) -  Sep 26, 2019   
    P2,  N=95, Recruiting, 
    This study demonstrated the utility of the PDOX model in allowing effective from non-effective drugs to be distinguished in a model in which the tumor was growing on the organ corresponding to that of the patient. Not yet recruiting --> Recruiting | Trial completion date: Mar 2023 --> Mar 2024 | Trial primary completion date: Mar 2023 --> Mar 2024